The NLC Health Impact Fund
Your access to the €10 trillion healthcare revolution
Why invest in healthcare
A shortage of healthcare professionals and an aging population: healthcare is one of the biggest challenges of our time. Yet the toughest challenges can turn into the most rewarding investments.
Your safest gateway to unlock the potential of this €10 trillion market is the NLC Health Impact Fund.
Why invest in the nlc health impact fund
Instead of investing in a single venture, you invest in the NLC Health Impact Fund, the newest flagship fund of the world's largest healthtech venture builder. You invest in a portfolio of 80-90 ventures from pre-seed to Series A/B and provides you access to healthcare innovations originating from world-renowned universities, hospitals and corporates, that are carefully vetted, supported and scaled by NLC.
the benefits of investing in our fund
the numbers
Get in touch and explore the opportunities
A selection of ventures in
the NLC health impact fund
The rising number of surgeries in healthcare systems like the National Health Service is challenging due to increasing demand and backlogs. However, new solutions like the Asclepius Platform aim to streamline assessments before and after surgery using digital tools and AI. By analyzing patient data, it helps doctors make better decisions, reduce complications, and improve patient outcomes. Designed with input from patients, it's a cost-effective way to make surgery safer and more efficient.
Nicolab tackles the challenge of stroke diagnosis and treatment by offering computational support through their portfolio of six algorithms. These algorithms analyze radiological images of acute stroke patients, providing fast and objective interpretation for physicians. With stroke affecting millions annually and significant economic burdens, Nicolab's solution improves decision-making speed and accuracy, allowing clinicians to assess stroke severity objectively and make timely treatment decisions.
Scinvivo introduces a solution for bladder cancer diagnosis with its imaging catheter, providing real-time, cross-sectional tissue images. Traditional methods often lead to unnecessary surgeries and missed tumors. By utilizing Optical Coherence Tomography technology, Scinvivo's catheter offers high-resolution imaging, enabling urologists to accurately diagnose bladder conditions. This approach reduces unnecessary surgeries but also enhances diagnostic accuracy, improving patient outcomes.
Intuescope, develops advanced tools to make endoscopy and colonoscopy procedures faster and safer. Despite being gold standard tests, traditional scopes have changed little over 40 years and often miss abnormalities. Intuescope's innovations aim to reduce procedure time, enhance detection accuracy, and support doctors with more automation, addressing the growing need for efficient and reliable endoscopic solutions.
Introducing Liftya, a solution for shoulder instability. Developed with a patented spherical hinge mechanism, Liftya mimics the natural shoulder joint movement, offering stability and full range of motion. Unlike traditional braces, Liftya promotes motor recovery and independence, reducing pain and healthcare costs for patients.
MLA Diagnostics improves melanoma diagnosis, offering personalized measurement of malignancy levels. Traditional diagnosis often leads to overtreatment or undertreatment, resulting in patient distress or undetected cancer progression. By analyzing methylation, our test provides accurate prognosis, enabling tailored treatment plans and saving lives. With the melanoma therapeutics market on the rise, our innovative solution is poised to make a significant impact, improve patient outcomes and create opportunities.
Laparoscopic surgery, while effective, faces limitations in low-resource areas due to cost and sustainability concerns associated with CO2 insufflation. Gasless laparoscopy provides an alternative, that are costly and difficult to use. To address these challenges, LORESA has developed an affordable and user-friendly gasless laparoscopy retractor, designed with input from surgeons worldwide, offering improved usability and cost-effectiveness. This innovation, aims to democratize laparoscopic techniques, benefiting rural hospitals and developing communities.
Axial Orthopaedics Inc. revolutionizes trauma treatment with their innovative intramedullary nailing system. Current systems often lead to bone misalignment and joint pain, blocking post-procedural recovery. Axial Orthopaedics's modular system offers greater flexibility in bone alignment and healing. This system not only addresses postoperative pain but also reduces complications. Its intra-operative modularity and rotational capabilities allow surgeons to achieve better fracture fixation and improved outcomes, filling a crucial gap in current technology.
Key considerations
As with all investments carrying risk, the value of your investment in NLC and its Health Impact Fund could be lost, in full or in part due to unexpected developments. Some of the key risks are listed below. Prospective investors are advised to consult the Information Memorandum of this Fund.
Restricted tradeability
As a closed-end fund, the interests are not freely tradeable. If an investor wishes to sell their fund holdings before the end of the 10-year term, their obtained returns might be negatively affected or the interests might not be tradable or will only be tradable to a limited extent because of lack of another person acquiring their interests. Investors could, thus, be bound to this investment longer than expected or desired.
Start-up risk
The Fund invests in healthtech startups, which are inherently of high risk. Several of the portfolio companies in which the Fund will invest will not be able to turn their current projects into fully commercialized products certified for medical use, negatively affecting the value of the investment.
Market risk
Many of the portfolio companies are projected to need one or more follow-on financing rounds to successfully launch their product on the market. While the fund itself can, inmost instances, also provide this follow-on financing, such investments always need to be matched by external investors. If the portfolio companies are unable to secure this funding, it might lead to a delay or a lack of sources to continue the developmental trajectories of one or more portfolio companies.
Insights
This webpage is a marketing material which has been prepared by NLC Fund Management B.V. (‘NLC’) with the purpose of sharing relevant information concerning the funds under their management. It does not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, which will only be made by means of an information memorandum and/or subscription documents. You may not rely on this webpage as the basis upon which to make an investment decision. This webpage does not purport to be complete on any topic addressed. NLC has not verified or analyzed the information included in this webpage for accuracy or completeness. NLC shall not bear any liability for the information contained in, or any omissions from, this webpage.